We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




MRI Contrast Agent Improves Detection of Lymph Nodes Metastases

By HospiMedica International staff writers
Posted on 24 Feb 2010
Adding the contrast agent gadolinium during magnetic resonance imaging (MRI) for primary tumor assessment was shown to improve accuracy for detecting lymph node metastases, according to a new review.

Gadolinium-enhanced MRI is primarily used to visualize primary tumors, highlight tumor vascularity, and increasingly to detect and evaluate lymph node metastases. More...
In this systematic review, the investigators recommend that contrast highlighting be included as a malignancy criterion when this agent is used for primary tumor visualization.

Wenche M. Klerkx, M.D., Ph.D., from the department of gynecology and obstetrics at the University Medical Center Utrecht (The Netherlands), and colleagues searched the literature for studies that compared the diagnostic accuracy of gadolinium-enhanced MRI for staging lymph node metastases with that of histopathologic examination. The researchers conducted a meta-analysis that encompassed more than 30 studies from the last 10 years and reported summary sensitivity and specificity of MRI for detecting nodal metastases. They published their findings online February 1, 2010, in the Journal of the National Cancer Institute.

The researchers found that overall accuracy of gadolinium-enhanced MRI for the detection of nodal metastases was moderate. They also concluded that incorporating contrast enhancement in the malignancy criteria improves the accuracy of this diagnostic test.

"We further advocate the use of uniform malignancy criteria, including contrast enhancement, for standardization of future evaluations,” the authors wrote in their article. "Gadolinium enhancement by itself does not have the diagnostic accuracy to replace histopathologic examination of lymph nodes; however, it can help identify suspicious lymph nodes that should be surgically collected for histopathologic examination.”

Study limitations included not all of the included studies reported diagnostic study quality, which precluded formal analyses based on the quality assessment items. A regression test for small-study effects was statistically significant, indicating that the retrieved studies had findings that may not be representative of the full range of evidence that has been produced (publication bias). In the overall analyses of the diagnostic accuracy of gadolinium-enhanced MRI for the detection of lymph node metastases, studies were pooled without regard to the primary tumor site.

Related Links:

University Medical Centre Utrecht





New
Gold Member
Breast Imaging Monitor
Barco Coronis Onelook MDMC-32133 32MP
Biochip Array Technology
Evidence MultiSTAT Drugs of Abuse Urine Multiplex Panel
Patient Preoperative Skin Preparation
BD ChloraPrep
Hypodermic Syringe
SurTract™ Safety Syringe
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Cedit: Shutterstock

New Light-Activated Platform Advances Glioblastoma Surgery and Postoperative Treatment

Glioblastoma, an aggressive primary brain tumor, infiltrates healthy tissue and resists complete surgical removal. Residual microscopic disease and the blood–brain barrier limit the effectiveness of adjuvant... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.